Mutka, Minna http://orcid.org/0000-0002-8380-7293
Virtakoivu, Reetta
Joensuu, Kristiina
Hollmén, Maija
Heikkilä, Päivi
Funding for this research was provided by:
Helsingin ja Uudenmaan Sairaanhoitopiiri
Academy of Finland
University of Helsinki including Helsinki University Central Hospital
Article History
Received: 24 May 2022
Accepted: 6 July 2022
First Online: 2 August 2022
Declarations
:
: Maija Hollmen own shares of Faron Pharmaceuticals and reports receiving funding from Faron for the preclinical development of anti-Clever-1 mAbs. The authors have no other relevant financial or non-financial interests to disclose.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the Helsinki University Central Hospital.
: Not applicable.
: Not applicable.